In this issue
Human Vaccines & Immunotherapeutics
Volume 9, Issue 6June 2013
View current issue
About the cover
Confocal images of CHO cells treated with different PTx concentrations for 12 h, negative control. For more information see Tan et al.Continue reading
Issue Highlights
Special Section: NIC23
Guest Editors: David Baxter, Manchester University Medical School; Manchester, UK
and Martin J. Guppy, ESPID in Milan, Paediatric Infectious Disease; Milan Italy
Most Popular Downloads
Vijaya Madhavi, Marjon Navis, Amy W. Chung, et al.
Thomas Gardner, Bennett Elzey and Noah M. Hahn
Ramesh Verma, Pardeep Khanna and Suraj Chawla
Jane Whelan, Susan Hahné, Guy Berbers, et al.
Mohan Bairwa, Manju Pilania, Meena Rajput, et al.
Important Journal Links
Landes Highlights
Articles of interest recently published in our other journals
Specific temperature-induced perturbations of secondary mRNA structures are associated with the cold-adapted temperature-sensitive phenotype of influenza A virus. Chursov et al. RNA Biology 9(10); October 2012.
Differential stimulation of hepatitis C virus RNA translation by microRNA-122 in different cell cycle phases. Carmen Fehr, K. Dominik Conrad and Michael Niepmann. Cell Cycle 11(2). January 15, 2012.
Selfness-nonselfness in designing an anti-B19 erythrovirus vaccine. Candida Fasano and Darja Kanduc. Self/Nonself 2(2); April/May/June 2011. Review.
Recombinant adeno-associated virus expressing a modified transcription factor triggered by the hepatitis C viral protease NS3/4a. Chul Hyun Joo. Bioengineered Bugs 2(3); May/June 2011.
Editor-in-Chief
Ronald Ellis PhD
Senior Vice President R&D and Chief Technology Officer
NasVax Ltd., Ness Ziona, Israel
Medline/PubMed, PubMed Central, Science Citation Index Expanded (available as the ISI Web of Science, ISI Alerting Services, Biosis Previews and Biological Abstracts).
Open Access in
Human Vaccines & Immunotherapeutics
Human Vaccines & Immunotherapeutics offers a highly competitive open access fee for authors who wish for free access to and distribution of published articles. Authors retain copyright of their work by utilizing a Creative Commons attribution license. Open Access papers will be submitted to PubMed Central immediately upon final publication of each issue.
Open Access Fees
Research Papers and Reports, OA fee is $750.00 USD
Reviews, Brief Reports and Short Communications, OA fee is $500.00 USD
All other types of papers, OA fee is $250.00
Find us on Facebook
Submit your paper to Human Vaccines & Immunotherapeutics
Human Vaccines & Immunotherapeutics (HV&I) utilizes an online submission and tracking system designed to provide efficient service to authors. Through the online system, author files are automatically converted to PDFs, submissions are acknowledged by email, and authors can track their manuscript through the stages of the peer review process.
Click here to submit your manuscript to HV&I.
HV&I is indexed in Medline/PubMed and in the Science Citation Index Expanded.
Upcoming Meetings
Superbugs & Superdrugs
March 4-5, 2013
London, UK
3rd Annual Vaccine World Summit
March 5-7, 2013
Pune, India
Host Response in Tuberculosis &
Tuberculosis: Understanding the Enemy- Keystone Symposia
Mar. 13-18, 2013
Whistler, BC CA
Immune Activation in HIV Infection: Basic Mechanisms and Clinical Implications- Keystone Symposium
April 3-8, 2013
Breckenridge, CO USA
World Vaccine Congress & Expo USA
April 16-18, 2013
Washington DC
The Innate Immune Response in the Pathogenesis of Infectious Disease- Keystone Symposium
May 10-15, 2013
Ouro Preto, Brazil
World Vaccine Congress & Expo Europe
October 16-17, 2013
Lille, France
